Physician profile
Jacqueline Chan
NPI 1801094032
$4,335.24
in general payments reported to CMS, 2019-2025
35 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,176 · 2020: $462 · 2021: $1,266 · 2022: $12.16 · 2023: $111 · 2024: $126 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.82 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $463.01 | 2019-2021 | |
| Biogen, INC. | $427.11 | 2019-2025 | Vumerity, Tysabri |
| Alexion Pharmaceuticals, INC. | $359.53 | 2019-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $278.54 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $229.20 | 2019 | |
| Genzyme Corporation | $214.83 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $199.28 | 2019-2021 | |
| Abbvie INC. | $181.33 | 2021 | |
| Emd Serono, INC. | $155.91 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $151.36 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $150.02 | 2020-2021 | |
| Genentech USA, INC. | $136.78 | 2019-2023 | Ocrevus, Enspryng |
| Adamas Pharmaceuticals, INC. | $132.08 | 2019-2021 | |
| Amgen INC. | $131.04 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $114.46 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $111.53 | 2019-2020 | |
| Tg Therapeutics, INC. | $106.33 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $89.95 | 2019-2021 | |
| Pfizer INC. | $88.61 | 2023 | |
| Avanir Pharmaceuticals, INC. | $87.49 | 2019 | |
| Acorda Therapeutics, INC | $75.42 | 2019 | |
| Acadia Pharmaceuticals INC | $74.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $67.26 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $66.39 | 2021 | |
| Lilly USA, LLC | $51.35 | 2021 | |
| Genentech, INC. | $40.18 | 2019 | |
| Aimmune Therapeutics, INC. | $25.72 | 2024 | |
| Neurocrine Biosciences, INC. | $21.68 | 2019 | |
| Ironshore Pharmaceuticals INC. | $20.94 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.76 | 2019 | |
| Mdd US Operations, LLC | $16.44 | 2019 | |
| Ge Healthcare | $14.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.12 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Livanova USA, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.